Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression By Ogkologos - July 16, 2025 637 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATRACTIB study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Development of Secondary T-Cell Cancers After the Use of CAR T-Cells... January 29, 2024 Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for... August 27, 2025 Lung Cancer Treatment Research Enters a New Era October 17, 2023 How to Prepare for Lung Cancer Treatment to Help With Recovery December 15, 2022 Load more HOT NEWS GENIE Registry Identifies Cancer Types Enriched with KRASG12C Somatic Mutations Into the archives: the story of HPV and cervical cancer ESMO Asia Congress 2023, 1-3 December 2023, Singapore Beloved Kindergarten Teacher Who Inspired Her Community Dies of Breast Cancer...
